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ScienceDirectThe biosynthetic pathways for patellamide and related natural
products have recently been studied by structural biology.
These pathways produce molecules that have a complex
framework and exhibit a diverse array of activity due to the
variability of the amino acids that are found in them. As these
molecules are difficult to synthesize chemically, exploitation of
their properties has been modest. The patellamide pathway
involves amino acid heterocyclization, peptide cleavage,
peptide macrocyclization, heterocycle oxidation and
epimerization; closely related products are also prenylated.
Enzyme activities have been identified for all these
transformations except epimerization, which may be
spontaneous. This review highlights the recent structural and
mechanistic work on amino acid heterocyclization, peptide
cleavage and peptide macrocyclization. This work should help
in using the enzymes to produce novel analogs of the natural
products enabling an exploitation of their properties.
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Introduction
Small molecules with potent biological properties are
commonly isolated from bacteria. Analysis of well estab-
lished rules for anthropogenic pharmaceuticals [1] indicates
that in comparison, natural products tend to have more
stereo centres and nitrogen atoms but are, in general, not
wildly different [2,3]. Natural products that have some
undesirable properties as medicines, but they can be
improved by chemical modification. Natural products,
including modified variants, are a major component inCurrent Opinion in Structural Biology 2014, 29:112–121 the pharmaceutical armory for treating diseases ranging
from bacterial infection to cancer to immune suppression
[4]. Synthetic biology promises, amongst other deliver-
ables, the ability to tailor enzymes in biosynthetic pathways
to create natural product variants with desirable properties
in the quantities required for drug development [5].
Peptide based natural products are particularly attractive
from a chemical point of view; amino acids share a common
standard in connectivity (the amide bond) with an almost
infinitely configurable element (the side chain). One can
thus ‘dial’ in chemical and structural properties into a
shared basic design. Crucially, in the same way as no
two proteins need to share any biological property, pep-
tides by virtue of their different side chains can have
divergent properties. The cyanobactin family of riboso-
mally synthesized and post-translationally modified pep-
tides (RiPPs) are peptide macrocycles that exemplify this
diversity, ranging from six to over 20 residues, with diver-
gent sequences and very different biological properties
including P-gp inhibition, cytotoxicity, immunomodula-
tion, antifungal, antibacterial and antiviral properties [6].
Macrocyclic peptides are particularly appealing as they are
intrinsically resistant to protease degradation and several
cross membranes [7]. There is significant interest in their
biosynthesis with a view to exploiting this class of molecule
for novel drugs [8,9,10]. In this review, we use the example
of the patellamide (an eight-residue macrocyclic cyano-
bactin) [11] to structure our discussion. In this pathway a
single ribosomal seventy one-residue precursor peptide,
PatE, gives rise to two eight-residue macrocycles; patella-
mide A and patellamide C [11] (Figure 1a). PatE contains
two eight-residue core peptides and each is converted to
the corresponding patellamides (Figure 1b) by enzyme
action. Within PatE each core peptide is flanked by a
conserved five-residue protease signature (N-terminal), a
conserved three-residue macrocyclization signature (C-
terminal) and in addition PatE has a thirty seven-residue
leader peptide at N-terminus [11] (Figure 1a). During
synthesis the peptide bonds between the core peptide
and its flanking regions must be cut and the ends of the
core peptide joined (Figure 1b). The final products contain
oxazolines (derived from the heterocyclization of serine/
threonine) and thiazoles (oxidized form of thiazoline which
is derived from the heterocyclization of cysteine)
(Figure 1b). The two residues adjacent to the thiazoles
are epimerized from an L-configuration to D-configuration
(Figure 1b). The functions of the enzymes that convert
PatE into patellamides were first assigned by sequence
analysis (Figure 1c) [11]. There are many closely relatedwww.sciencedirect.com
Natural product biosynthesis Koehnke et al. 113
Figure 1
PatA
PatellinPatellamide A: R1 =CHMeEt; R 2,R 4=CHMe 2; R 3=H
Patellamide C: R1 =CHMe 2; R 2,R 3=Me; R 4=CH2Ph
PatD
PatF
PatG
protease DUF
DUFmacrocyclaseoxidase
prenyl transferase
heterocyclase / cyclodehydratase
(a) patA
(X)37
patB patC
GLEAS
Leader
Herocyclization
/ cyclic dehydration
Prenylation
Protease
site
Core
peptide
Patellamide C Patellamide A
Core
peptide
Macro
signature
VTACITFC AYD GVEPS ITVCISVC GEAYD
patD patE patF patG
(b)
(c)
R1
R3 R4
O
O
O
O O
O
OO
O
NH
HN
N
HN
O
H
N
N
H
R2
O
O
Macrocyclization
Oxidation
HN NH
Epimerization at Cα
Proteolysis
O
N
NN
N
N
S
S S
Current Opinion in Structural Biology
(a) The patellamide gene cluster contains genes patA to patG, coding for proteins PatA to PatG. The PatE protein contains: (1) a 37 residue leader
and (2) two core peptides, which are processed to give patellamides C and A [11]. The core peptides are flanked at their N and C termini; (b) the
final natural product patellamides C and A showing the chemical transformations during post-translational processing. The closely related patellin
which is prenylated is shown; (c) the enzymes which tailor the core peptide. PatG encodes two functions and in addition has a DUF. PatA
encodes the protease and also posses the same DUF.pathways in other marine organisms, such as the trunka-
mide and patellin (Figure 1b) biosynthetic pathway, that
utilise biosynthetic enzymes which are very similar to those
of the patellamide pathway [6,9,11]. Moreover, many of the
chemical reactions that are catalyzed by enzymes in the
patellamide pathway occur in the biosynthesis of other
natural products that are unrelated to cyclic peptides. We
herein discuss insights from these other pathways under
the corresponding chemical transformations observed in
the patellamide system.
Heterocyclization
The heterocyclase (or cyclodehydratase) class of enzymes
modify cysteine residues (and in some cases serine andwww.sciencedirect.com threonine residues, too) within the context of the core
peptide(s), to create thiazolines (or oxazolines)
(Figure 1b) and eliminate water [12]. Patellamides A and
C contain four heterocycles each and these five membered
rings profoundly change the chemistry and flexibility of the
peptide [13]. Their selective introduction is a powerful tool
to tune the molecular shape and activity of not only peptide
macrocycles, but also linear peptide natural product
families such as the antibacterial microcin peptides [14].
The microcin ‘Trojan horse’ antibiotic peptide MccC7 has
a C-terminal phosphoramidate that is linked to adenosine.
During the biosynthesis of the peptide an intermediate
with a C-terminal five membered succinamide ring is
synthesized by heterocyclization of the C-terminal AsnCurrent Opinion in Structural Biology 2014, 29:112–121
114 Catalysis and regulationresidue [15]. The structure of the enzyme responsible,
MccB, was revealed to have two domains. The larger of
the two (the C-terminal) adopts a classic adenylase super-
family fold whilst the fold of the smaller (N-terminal) was
novel [15]. MccB activates the substrate peptide carboxy
terminus by first converting it to an adenylate then the
amide of the side chain of Asn displaces AMP to give the
succinamide five membered ring. MccB catalyzes a second
adenylation reaction that adds adenosine to the peptide.
Domain 1 of MccB acts as a clamp holding the peptide
substrate for processing. More recently thiazole/thiazoline-
containing (modified) microcins [16], collectively known as
TOMMs have been studied [17,18]. Enzymatic charac-
terization revealed that the catalytic activity required ATP
and that full activity was only observed with two proteins
BalhC and BalhD, although BalhD was shown to catalyze
the reaction on its own, albeit very slowly [17]. Bio-
chemical data established that the protein functioned as
a kinase, phosphorylating the hemiorthoamide intermedi-
ate formed by cysteine attack at the preceding carbonyl
[17]. The formation of hemiorthoamide intermediates is
commonplace in food chemistry where thiazolines and
other five membered rings occur in heated proteins [19].
By analogy then, it could be that the irreversible step is
actually the removal of water (either by heat or by formation
of a phosphorous oxygen bond followed by elimination of
phosphate) and that the reversible formation of hemi-
orthoamides in a protein may in energetic terms be a
relatively low barrier process.
In the patellamide pathway, the enzyme PatD catalyzes
the formation of multiple thiazolines (from cysteine) and
oxazolines (from serine and threonine); the closely related
enzyme TruD (from the trunkamide pathway) only pro-
cesses cysteines with both enzymes operating in an ATP
dependent and processive manner [20,21]. It has been
shown that selenocysteine (a rare but known amino acid)
is processed to a selenazoline by both PatD and TruD
[22], making it possible that natural products could be
discovered that contain selenazoline or selenazole modi-
fications. The crystal structure of TruD [23] shows it to
be a three-domain protein (Figure 2a). Domains 1 and
2 are, in structural terms, essentially identical to the MccB
protein [15,23] with both proteins sharing a structural
zinc bound in the second domain. BalhC has sequence
homology to these two domains, whilst BalhD shares
homology with the third domain of TruD, which is
structurally novel [23]. Thus PatD-like enzymes can
be considered fusions of BalhC and BalhD.
NMR and assay data show that TruD produces AMP and
pyrophosphate (PPi), the hall mark of an adenylase or less
commonly a pyrophosphorylase mechanisms [23]
(Figure 2b). However, the loops that form the ATP
binding site in domain 2 of MccB [15] are absent in
the TruD structure (and in PatD-like sequences more
generally) [23], precluding ATP binding in the mannerCurrent Opinion in Structural Biology 2014, 29:112–121 seen in other adenylating enzymes [23]. An adenylase
rather than a kinase mechanism was proposed as the most
likely for TruD with the data in hand [23].
TruD was shown to have a preferred order of reactivity,
proceeding from the C-terminus [23]. The processivity
of the enzyme required the leader peptide to be attached
to the core peptide and similar observations had pre-
viously been made for the BalhC/D system [24,25]. All
the heterocyclase enzymes are promiscuous and tolerate
diversity in chemical and structural nature of amino acids,
which flank the target cysteine (or threonine, serine)
[20,21,24,25].
A very recent paper has reported the structure of the YcaO
domain from Escherichia coli with a bound nucleotide
[18] (Figure 2c). The product and substrate of YcaO
are unknown but the YcaO domain has the same structure
as the third domain of TruD and shares sequence
homology with BalhD [18]. The residues that ligate
the nucleotide are also conserved, essentially ruling out
the adenylase domain of TruD as the nucleotide binding
site [18] and disfavouring an adenylase mechanism for
TruD. The key chemical step in both TruD and BalhD is
the irreversible modification of the hemiorthoamide and
it is possible, but perhaps unlikely, that one operates by a
pyrophosporylation and the other by a kinase mechanism
(Figure 2b). It has been pointed out that adenylation and
phosphorylation share chemical similarities [26] and in
one case similar enzyme folds [27]. It is worth noting that
in the absence of substrate, YcaO produced AMP and PPi
[18], suggesting more work is needed to resolve the
mechanism(s) in detail.
Peptide cleavage and macrocyclization
In the patellamide pathway, two domains, one from the
PatG protein and one from the PatA protein, possess
sequences matching the classic subtilisin fold [11]. How-
ever, PatA catalyzes the cleavage of the precursor peptide
at the N-terminal protease site, removing the leader
peptide (Figure 1a). The PatG domain catalyzes the
formation of the macrocyclic peptide (simultaneously
removing the C-terminal protease signature) [11]. The
structure of the protease domain from PatA without
substrate (Fig. 3ai) was determined independently by
two groups [28,29]. The apo structure of a close PatA
homolog, PagA, was also reported [29]. PatA possesses a
classic serine protease fold but in both native PatA
structures, the catalytic triad is perturbed from the classic
arrangement [28,29]. In a PatA variant (catalytic serine
mutated to alanine) [28] and in PagA [29] the key
histidine of the triad adopts its conventional confor-
mation. It would seem unlikely that mis-setting of the
catalytic triad in PatA is a consequence of the lack of the
C-terminal domain, as similar protease activity is
observed in both forms [29]. This leaves two expla-
nations for the misalignment: either crystal packing orwww.sciencedirect.com
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(a) The structure of TruD (cartoon with a-helices in red; b-sheets in yellow; b-turns in green) shows it has three domains [23]. Domains 1 and
2 are very similar to a known adenylase MccB [15] and to BalhC from the TOMM pathway. Domain 3 has a novel structure and is related in
sequence to BalhD in the TOMM pathway [17]; (b) heterocyclization of amino acids (cysteine X = S, selenocysteine X = Se, serine/threonine
X = O) to yield azoline rings. TOMMS were first predicted to go through a hemiorthamide intermediate (circled). It is likely that in the patellamide
biosynthetic pathway, heterocyclization goes through the same central intermediate. In the TOMM system [17] ATP is used to phosphorylate
(Y = ADP, Z = PO4
3) the intermediate, whereas in the patellamide pathway the intermediate was proposed to be adenylated (Y = AMP,
Z = P2O7
4) [23]. Either mechanism would be irreversible and would promote elimination yielding the azoline. There is a third possibility,
pyrophosphorylation (Y = P2O7
4, Z = AMP), which although rare, has precedent and is consistent with much of the published data; (c) a cartoon
representation of the structure of the YcaO domain [18] from E. coli has located the nucleotide binding site. This domain is boxed and is
structurally similar to domain 3 of TruD [23], shown in Figure 2a. The binding of ATP to domain 3 disfavors the adenylase mechanism previously
proposed [23]. The protein is colored as Figure 2a, the nucleotide analog AMP-PNP is shown in space fill with carbon atoms in green, nitrogen
atoms in blue and oxygen atoms in red.missing protein–protein interactions (from the substrate).
Unfortunately the PagA structure, which has the correct
constellation of active site residues, does not resolve the
argument, as it has extensive crystal contacts around its
active site which could mimic some protein–protein
interactions [29]. Cleavage of PatE by PatA occurs at
a very slow rate (orders of magnitude slower than sub-
tilisin) [28,29] and it has been suggested a slow pro-
tease might be important in helping regulate the timing of
the multiple chemical steps during processing [29].
The crystal structure of the macrocyclase domain of PatG
(Figure 3aii), determined by two laboratories [29,30],www.sciencedirect.com shows it does indeed possess a subtilisin fold (thus
structurally similar to PatA [28,29]). PatG does how-
ever possess a unique and additional structural feature:
two helices that are inserted between a helix and a strand
of the subtilisin fold (Figure 3b). These helices, which
have been termed as the ‘capping’ or ‘macrocyclization’
insert, sit directly above the catalytic site. Sequence
alignment shows that the entire macrocyclase superfam-
ily has an insertion in this region but neither length nor
the sequence of the insertions have any obvious con-
servation. For example, the insertion in one ortholog
(TenG) is eight residues longer whilst another (AnaB90)
is four residues shorter than PatG [30]. As yet, noCurrent Opinion in Structural Biology 2014, 29:112–121
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(a) Crystal structure of the PatA protease domain [28,29] in cartoon representation (colored as in Figure 2a); (b) structural alignment of the PatG
macrocyclase domain [30] (subtilisin fold in green and ‘capping’ or ‘macrocyclization’ insert in red) with Akt1, a subtilisin protease (magenta); (c)
crystal structure of the PatG macrocyclase domain in complex with substrate peptide VPAPIPFPAYDG (only PIPFPAYDG ordered) [30]. The
cartoon of the protein is colored as 2b, the peptide is shown in stick with carbon atoms of the core peptide in black, carbon atoms of the
macrocyclization signature in cyan, nitrogen atoms blue and oxygen atoms red; and (d) mechanism for PatG macrocyclase domain catalyzed C-
terminal cleavage of the core peptide to form an acyl enzyme intermediate and subsequent decomposition of this intermediate by the incoming
amino terminus of the core peptide to form the macrocycle [30]. The core peptide is shown in black, the macrocyclisation signature of the
substrate is shown in magenta. The cis peptide is shown in orange. The protein residues are colored in green for those in the subtilisin fold and
red for those in the insert.relationship between the insertion and the size or com-
position of the macrocycle has been reported. Protease
substrate residues are conventionally labelled from the N
to C terminus as P5 P4 P3 P2 P1–P10 P20 P30 P40 P50. In
general, subtilisins bind their substrates as a b-strandCurrent Opinion in Structural Biology 2014, 29:112–121 with the protein–protein recognition occurring N-term-
inal to the scissile bond (P1–P10), that is, residues P5 to P1
of the substrate peptide; this is exemplified by PatA
(Figure 1a). This P5 to P1 binding cleft is blocked in
PatG by changes in the loop structure and insertion ofwww.sciencedirect.com
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in PatG homologs [30]. As a result PatG actively pre-
vents substrates from binding with an extended b-strand
conformation for residues P5 to P1 [30]. The crystal
structure of a complex between an inactive PatG mutant
(Figure 3c) and a peptide substrate (P8-VPAPIPF-
PAYDG-P40) has been determined [30]. The N-term-
inal region of the substrate curves away from the protein
active site (P8–P6 (VPA) are disordered). The P5 (P) and
P4 (I) residues do not make any contact with the protein,
the P3 (P) residue makes only a few contacts and the
aromatic side chain of residue P2 (F) sits in a shallow
pocket. The lack of contact is consistent with the prom-
iscuity of the macrocyclase domain since it is largely
insensitive to the identity of residues within the core
peptide [31]. The complex reveals a number of very
specific interactions between the C-terminal region of
the substrate P10 P20 P30 (AYD) and residues from the
macrocyclization/capping insert [30]. PatG stands as a
mirror opposite of subtilisin where recognition is N-
terminal and promiscuity C-terminal. For a PatG sub-
strate, there is one additional requirement: a proline
residue or a thiazoline at P1 [31]. The PatG substrate
complex shows that the proline of the substrate adopts a
cis configuration of the P2–P1 substrate bond [30]. A
trans peptide (b-strand) configuration would result in
clashes with the macrocyclase due to the conserved
insertions and thus only substrates capable of adopting
a cis (proline) or cis-like (thiazoline) configuration will
bind to PatG, rationalizing the requirement at P1. PatG
does form an acyl enzyme intermediate with its peptide
substrate [30] and a mechanism in which this inter-
mediate is decomposed by attack of the free amino
terminus of the core peptide has been proposed
(Figure 3d). An elegant study has shown that the PatG
acyl enzyme intermediate can be decomposed with short
peptides [29]; in essence demonstrating that PatG can
function as a true transpeptidase. The rate of macrocy-
clization by PatG is slow [29,30], but this does not
necessarily imply the enzyme is a poor catalyst; the
uncatalyzed rate for peptide macrocyclization has not
been reported and in our hands no spontaneous macro-
cyclization was observed [30].
Prenyl transferases, DUF and oxidase
Although patellamides A and C are not prenylated, the
related patellin (Figure 1b) and trunkamide natural
products are (Figure 1b) [32–35]. The prenyl trans-
ferases from patellamide like pathways in Lyngbya aes-
tuarii (LynF) and Prochloron spp. (TruF1) have been
characterized biochemically [35,36]. LynF prenylates a
tyrosine residue on the phenol group to generate the
corresponding allyl phenyl ether intermediate which
then spontaneously undergoes a Claisen re-arrangement
to yield the ortho-substituted phenol [36]. On the other
hand, TruF prenylates serine and threonine residues on
the hydroxyl side chain [35] (Figure 1b). The structurewww.sciencedirect.com of PatF from the patellamide pathway reveals that it
does indeed adopt the classic TIM barrel fold
(Figure 4a) seen in other prenyl transferases but no
enzymatic activity was detected [37], consistent with
the lack of prenylation of patellamides A and C. A
detailed analysis of PatF reveals that two residues,
His125 and Met136, are located at positions that are
usually occupied by conserved and catalytically active
Asp and Lys residues in a known prenyl transferase
(dimethylallyl tryptophan synthase from Aspergillus
fumigatus) [38], rationalizing the inactivity of PatF. Ot-
her cyanobactin prenyl transferases possess the Asp and
either a Lys or Arg at these key positions [37]. Whether
PatF has another role in the synthesis of patellamides A
and C, and if not why PatF is conserved in the gene
cluster, remains unknown.
Both PatA and PatG are multi-domain proteins and both
contain a C-terminal domain of unknown function (DUF)
[11] (Figure 1c). The sequences of the two DUF domains
are homologous and are found in PatA and PatG homologs
of other patellamide like biosynthetic clusters [39]. A
number of roles for the DUF domain have been con-
sidered including epimerization of the two residues in
patellamide A and C (Figure 1b). The pKa of the Ca
proton will be lowered by the adjacent thiazoline due to
resonance stabilization (Figure 4b); the loss of aromaticity
in the thiazole that would occur upon stabilization of the
negative charge would be expected to raise the pKa. For
this reason, it is commonly assumed epimerization follows
heterocyclization and precedes oxidation, but this has not
been established. Epimerization has been proposed to be
chemically spontaneous [40], if true, DUF domains may
have no role in patellamide biosynthesis. The question
then would be why the DUF domains are so well con-
served in patellamide like biosynthetic gene clusters?
The structure of the DUF domain from PatG has been
determined and the protein is found as a dimer with two
zinc ions at the interface [39] (Figure 4c). The zinc ion
binding residues are not conserved in other DUF domains
and since the dimerization depends on the zinc, it is
unclear whether other domains are dimers [39]. The fold
of the DUF domain is novel but gave no clue as to a
potential function [39]. It was established that the DUF
domain does not bind linear precursor peptides, nor linear
precursor peptides with four heterocycles [39]. Further
experiments are needed to establish whether the DUF
domain binds the macrocycle (or perhaps the core peptide
alone). Secondly, an evaluation of the chemical sponta-
neity or otherwise of epimerization in patellamide C is
also needed before a final assessment of the DUF domain
activity can be made.
The only domain in the patellamide biosynthetic path-
way without a structure is the oxidase (dehydrogenase)
domain of PatG (Figure 1c). The domain is conserved
in PatG homologs from patellamide-like pathwaysCurrent Opinion in Structural Biology 2014, 29:112–121
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Natural product biosynthesis Koehnke et al. 119(Figure 4d). Sequence analysis identifies the domain as
FMN dependent and a recent biochemical analysis of the
related thiazoline oxidase (which is a separate protein) in
the microcin pathway has been reported [41]. This study
showed FMN was bound and identified residues crucial
for activity [41]. The domain belongs to the class of FMN
oxidases most closely resembling the structure 3EO7
(determined by www.jcsg.org). Although the TOMM
and patellamide enzymes are related in sequence, the
basis of substrate recognition remains unclear since
microcin is linear and patellamides are macrocycles. A
recent study has shown that one homolog of the PatG
oxidase domain can oxidize both linear and macrocyclic
thiazoline containing substrates [42], whereas another
homolog appeared only to operate on a macrocyclic sub-
strate [42].
Future prospects
The patellamide biosynthetic pathway is comprised of
multiple different chemical steps (thus enzymes) and this
has made for particularly interesting mechanistic and
structural studies. The interest in this specific biosyn-
thetic pathway is driven by the potential utility of the
compounds that can be made. Several studies have
reported the in vitro and in vivo biotechnological appli-
cation of the pathway to make novel compounds
[42,43,44]. In one in vitro approach the slow protease
step catalyzed by PatA has been replaced by engineering
of the PatE so that trypsin can be used instead; this step
has greatly accelerated the production and increased the
yield of patellamide analogs [42]. Despite all these
efforts, the order of the epimerization, macrocyclization
and oxidation remains to be experimentally verified.
Important questions also remain to be answered about
the relationship between the macrocyclase sequence with
respect to macrocycle ring size, the mechanism of hetero-
cyclization, the precise substrate for oxidation and the
nature of epimerization. Answering these questions will
not only enhance our knowledge of the chemistry of the
enzymatic reactions found in the patellamide pathway
(and other natural product biosynthetic pathways), but
should allow a greater diversity of analogs to be created
both in vivo and in vitro. Two principal bottlenecks in the
in vitro production of analogs remain [42]. Firstly the
macrocyclase is slow and is the rate-limiting step in the
whole process. Secondly the requirement for the leader
peptide for introduction of heterocycles means that PatE(a) The structure of PatF [37] represented as Figure 2a. Although the structu
biosynthetic pathways, homologs of PatF have been shown to be active [35
thiazoline. The, study of a chemically related compound has led to the sugg
[40]. However, an enzyme catalyzed processes has not been formally ruled
cartoon representation of the structure of the PatG C-terminal DUF [39] rev
Figure 2a, the second monomer has duller colors; and (d) the oxidase dom
pathways with PatG homologs. Clustal Omega sequence alignment of the N
didemini), ArtG (Arthrospira platensis), MicG (Microcystis aeruginosa NIES-2
and TriG (Trichodesmium erythraeum IMS101). Figure created using ALINE.
www.sciencedirect.com can only be economically produced by expression in a
heterologous host, which limits the chemical diversity
within the final patellamide analog. Resolving these
issues would transform the prospects for large-scale pro-
duction of very diverse analogs. PatD has been shown to
be activated in trans by addition of exogenous leader [43]
and this suggests there is scope to overcome at least one of
the bottlenecks.
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